CAR-T cell therapy was pioneered at Penn by Dr. Carl June and has the potential to transform cancer therapy. Novartis has licensed the technology from Penn and has received very encouraging response from the FDA, which is very likely to approve the therapy.
The therapy was approved by the FDA. This is really exciting.
The treatment is $475,000, according to a NPR report quoting Novartis.
I heard that report too, @57special. How exactly does that work, I wonder. I mean who could actually pay that??
Health insurance companies, I assume, but who knows? Nothing about the US health system makes any damn sense to me.
They did mention that if the treatment didn’t work there would be no charge. In other words, if you die, you don’t have to pay.
Yes this kid of specialty drugs are covered by insurance. No one is paying that kind of money out of pocket.